CN105326581A - Method of preparing polyethylene glycol and protein fiber combined artificial cardiac valve - Google Patents
Method of preparing polyethylene glycol and protein fiber combined artificial cardiac valve Download PDFInfo
- Publication number
- CN105326581A CN105326581A CN201510633718.9A CN201510633718A CN105326581A CN 105326581 A CN105326581 A CN 105326581A CN 201510633718 A CN201510633718 A CN 201510633718A CN 105326581 A CN105326581 A CN 105326581A
- Authority
- CN
- China
- Prior art keywords
- polyethylene glycol
- eggshell membrane
- pegda
- combined artificial
- protein fibre
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Prostheses (AREA)
Abstract
The invention discloses a method of preparing a polyethylene glycol and protein fiber combined artificial cardiac valve and belongs to the field of biomedical materials. The method comprises: covering egg shell membrane protein fiber with photo-crosslinked polyethylene glycol hydrogel to obtain a composite material, and preparing the composite lamellar artificial cardiac valve through crosslinking by further using a molecular crosslinking agent (such as glutaraldehyde). The polyethylene glycol hydrogel is prepared by means of photo-crosslinking, ensuring the integrity of artificial valve materials, protecting the covered protein fiber from the in-vivo enzymatic decomposition and preventing calcification of the artificial valve. The artificial cardiac valve material prepared by the method simulates the lamellar structure of human aortic valves and has mechanical properties similar to those of the human aortic valves, with good biocompatibility guaranteed, and the need of a replacement receptor for high valve durability, good tissue compatibility and dispensing with a lifetime of anticoagulation can be met.
Description
Technical field
The present invention relates to biology medical material technical field, be specifically related to one and prepare Polyethylene Glycol-valvular method of protein fibre combined artificial.
Background technology
Valvular heart disease jeopardizes a kind of important diseases of human health, valvular calcification and fibrosis cause left ventricular outflow tract to block and aortic valve severe stenosis, so far any surgical operation and medicine is not had can to cure the diseases such as calcified valves pathological changes, the way of unique feasible is valve replacement, is applied to now clinical artificial valve and comprises mechanical valve prosthesis and biovalve.But need after Mechanical prosthetic valve replacement to take anticoagulation medicine throughout one's life, otherwise there will be the complication such as thrombosis.Consider that mechanical valve prosthesis implants and can cause untoward reaction, biovalve produces in 20 century 70s and grows up gradually.Now, feasible biological cardiac valves has following several types: pig xenogenesis valve, bovine pericardium valve, allogeneic valve (also cry homotransplantation, derive from donor) and autograft (coming from the tissue of autologous patient).Allograft and xenotransplantation can bring out the growth of fibrous tissue, can control between 0.2-1.8% by the sickness rate of obstructive thrombus, are controlled between 2 ~ 4% by valvular function sexual disorders disease incidence.But along with the increase of transplant time, biovalve is very easily decayed and calcification, and average life is only 7-20, particularly for teenager transplant recipient crowd, the misery of Repeated Operation will be faced with.Therefore, need development to have the artificial valve of better structure and biological property, strong to valve durability with satisfied displacement receptor, histocompatibility good and without the need to lifelong anticoagulant demand.
Summary of the invention
The object of the invention is to take the problems such as the calcification of anticoagulation and biovalve and immunologic rejection throughout one's life for artificial mechanical valve prosthesis conventional on Present clinical, one is provided to prepare Polyethylene Glycol-valvular method of protein fibre combined artificial, the egg membrane protein matter fiber of good mechanical performance and the good Polyethylene Glycol of biocompatibility is utilized to prepare complex layered Cardiac valve prosthesis for raw material, and by regulating the number of plies of egg film, the volume of polyglycol solution and concentration control thickness and the intensity of complex layered Cardiac valve prosthesis, there is important clinical value.
For achieving the above object, technical scheme of the present invention is as follows:
One prepares Polyethylene Glycol-valvular method of protein fibre combined artificial, the method is for raw material with eggshell membrane and Polyethylene Glycol, first the laminar composite of the coated protein fibre of polyethylene glycol hydrogel is prepared by photo-crosslinking method, then utilize molecule crosslinked dose to carry out chemical crosslinking, obtain described Polyethylene Glycol-protein fibre combined artificial cardiac valve.The method specifically comprises the steps:
(1) preparation of PEGDA: by Polyethylene Glycol (poly (ethyleneglycol), write a Chinese character in simplified form PEG) with acryloyl chloride through chemical reactive synthesis and the polyethyleneglycol diacrylate of purification Photocrosslinkable (poly (ethyleneglycol) diacrylate, writes a Chinese character in simplified form PEGDA);
(2) pretreatment of eggshell membrane: to be immersed in by the eggshell membrane after clean in PBS solution and to be placed in 4 DEG C of refrigerators and store, is cut into the sample of required form and size by eggshell membrane before photo-crosslinking, and be placed in the pre-gelling solution of PEGDA and soak more than 30 minutes;
(3) prepare polydimethylsiloxane (PDMS) template of required size and thickness, PDMS template central authorities hollow out one with the white space of eggshell membrane sample same shape and size, this PDMS template is placed on a slice to be had
on the microscope slide of coating, the white space then in PDMS template places pretreated eggshell membrane sample, and sample supplements PEGDA pre-gelling solution again and filled up in PDMS template central clear region, in PDMS template upper cover, another sheet has
the microscope slide sealing of coating;
(4) utilize cold white light or ultraviolet light cross-linking, the pre-gelling solution of PEGDA on eggshell membrane surface is cross-linked to form PEG-hydrogel, the final complex layered materials forming the coated eggshell membrane of PEG-hydrogel; According to cold white light be cross-linked, crosslinking time is 1-2 minute; According to ultraviolet light cross-linking, crosslinking time is 10-30 minute.
(5) step (4) gained complex layered materials is immersed in molecule crosslinked dose of (as glutaraldehyde) solution, after chemical crosslinking, namely obtains Polyethylene Glycol-protein fibre combined artificial cardiac valve.
In above-mentioned steps (2), the cleaning course of eggshell membrane is: remove the egg yolk in raw egg and Ovum Gallus domesticus album, after eggshell membrane and eggshell being peeled off, uses washed with de-ionized water from egg air chamber; Then acid soak method is used to remove calcium carbonate (CaCO residual on eggshell membrane
3) granule, then it is clean to spend Ion Cleaning.Use the CaCO on acid soak method removal eggshell membrane
3during granule, the acid adopted is the acetum of concentration 1-8mol/L, and the processing time is 2-12 hour, and treatment temperature is 4 DEG C; After adopting this technique to ensure acid treatment, egg membrane protein matter fiber can intactly preserve, and mechanical property is unaffected.
In above-mentioned steps (2), the PEGDA that step (1) obtains first is prepared into the pre-gelling solution of PEGDA, in the prepared pre-gelling solution of PEGDA, the pre-gelling solution of PEGDA be cross-linked for cold white light is containing mass percent 10-30%PEGDA (molecular weight 1000-3400g/mol), percent by volume 1-2% triethanolamine (triethanolamine, write a Chinese character in simplified form TEOA), the PBS solution of 10 μm of ol/L eosins (EosinY) and percent by volume 0.375%N-vinyl pyrrolidone (N-vinylpyrrolidone writes a Chinese character in simplified form NVP); The pre-gelling solution of PEGDA for ultraviolet light cross-linking is the PBS solution containing 3g/LIrgacure2959 (2-hydroxy-40-(2-hydroxyethoxy)-2-methylpropiophe-none).
In above-mentioned steps (3), the thickness making PDMS template is determined (thickness of monolayer eggshell membrane is 60-100 μm) by the number of plies of adopted eggshell membrane, PDMS template thickness 0.3-1mm.
In above-mentioned steps (5), described molecule crosslinked dose is glutaraldehyde solution, and glutaraldehyde mass percent concentration is 0.25-2%; The chemical crosslinking time is 2-12 hour.
Design principle of the present invention is as follows:
The present invention makes composite by photo-crosslinking polyethylene glycol hydrogel coated egg membrane protein matter fiber, utilizes molecule crosslinked dose (as glutaraldehyde) crosslinked further and prepares complex layered Cardiac valve prosthesis.The present invention is with eggshell membrane and Polyethylene Glycol for raw material, and wherein eggshell membrane abundance, is made up of protein fibre; And Polyethylene Glycol is the macromolecular material with good biocompatibility and biologically inert comparatively commonly used; the integraty that polyethylene glycol hydrogel not only ensure that artificial valve's material is obtained additionally by optical cross-linking method; and protect coated protein fibre and stop in its body and degraded by enzymolysis, and prevent the calcification of artificial valve.In addition, by changing the concentration of coated eggshell membrane quantity and polyethylene glycol hydrogel and volume to control thickness and the intensity of valve material, with the individual demand of satisfied different patient.Artificial heart valve membrane material prepared by this kind of method has imitated the layer structure of human aortic lobe, achieve the mechanical property close with it, ensure that good biocompatibility simultaneously, displacement receptor, histocompatibility strong to valve durability can be met good and without the need to lifelong anticoagulant demand.
Compared with existing cardiac valve technology of preparing, beneficial effect of the present invention is embodied in:
1, the present invention realizes the mechanical performance similar to human body valve using eggshell membrane as inner layer material; Outer coated PEGDA hydrogel provides good biocompatibility and biologically inert, and the protein fibre of protection internal layer is not degraded by enzymes.
2, the Polyethylene Glycol-protein fibre combined artificial cardiac valve of the present invention's proposition, can overcome existing machinery lobe needs to use anticoagulation and the problem such as biovalve vivo degradation and calcification throughout one's life.
3, the present invention can realize according to added egg rete number and polyglycol solution volume to prepare the complex layered Cardiac valve prosthesis of different-thickness and intensity.It is 0.3-1mm that the thickness of prepared valve material can make thickness according to demand.The mechanical strength of prepared valve material is determined by the number of plies of added eggshell membrane, the volume of PEGDA hydrogel and concentration.Elastic modelling quantity >=the 3.3MPa of prepared valve material, percentage elongation is greater than 35%.
Accompanying drawing explanation
Fig. 1 is the stereoscan photograph of the protein fibre of original eggshell membrane; Wherein: (a) is eggshell membrane skin; B () is eggshell membrane internal layer.
Fig. 2 is that PDMS masterplate legal system is for Polyethylene Glycol-protein fibre straticulate structure schematic diagram.
Fig. 3 to be employing 4 layers of eggshell membrane and mass percent concentration be 600 μm of thick Polyethylene Glycol-protein fibre complex layered materials prepared by 20%PEGDA solution (molecule crosslinked dose process before).
Fig. 4 to be employing 4 layers of eggshell membrane and mass percent concentration be 600 μm of thick Cardiac valve prosthesiss prepared by 20%PEGDA solution (molecule crosslinked dose process after).
Fig. 5 to be 4 layers of eggshell membrane and mass percent concentration be 600 μm of thick Cardiac valve prosthesiss prepared by 20%PEGDA solution after glutaraldehyde cross-linking around the subcutaneous embedding of mice is after 2 weeks the HE stained photographs of tissue slice; Wherein: (a) is 4 times of enlarged drawings; B () is 10 times of enlarged drawings.
Fig. 6 to be 4 layers of eggshell membrane and mass percent concentration be 400 μm of thick Cardiac valve prosthesiss soak after glutaraldehyde cross-linking and in type i collagen enzyme after 2 weeks elastic modelling quantity prepared by 20%PEGDA solution.
Detailed description of the invention
Below in conjunction with embodiment and accompanying drawing, technical scheme of the present invention is described further.
The present invention is that egg film is by being rich in collagen protein and keratic fibrous reticular membrane structure with eggshell membrane and Polyethylene Glycol for raw material.By the protein fibre of egg film and polyethylene glycol hydrogel compound are prepared Cardiac valve prosthesis.Technical process of the present invention is: egg film raw material → removal CaCO
3granule → PDMS stamp fabrication → eggshell membrane fiber and PEGDA hydrogel photo-crosslinking → molecule crosslinked dose of chemical crosslinking → Cardiac valve prosthesis.Detailed process is as follows: by Polyethylene Glycol (PEG, mean molecule quantity 3350g/mol) react prepare polyethyleneglycol diacrylate (PEGDA) [ZhangX with acryloyl chloride, XuB, PuperiDS, YonezawaAL, WuY, TsengH, CuchiaraML, WestJL, Grande-AllenKJ.IntegratingValve-InspiredDesignFeaturesIn toPoly (ethyleneglycol) HydrogelScaffoldsforHeartValveTissueEngineering.ActaBiom aterialia2015; 14:11-21.].Remove the egg yolk in raw egg and Ovum Gallus domesticus album, from egg air chamber, eggshell membrane is carefully peeled off, washed with de-ionized water 3 times, egg film is immersed in the CaCO on acetum removal egg film
3granule (saving eggshell membrane urporotein fibre structure, Fig. 1), is stored in PBS solution at 4 DEG C.Above-mentioned eggshell membrane to be soaked in before photo-crosslinking in PEGDA solution more than 30 minutes.Conventional method is adopted to prepare polydimethylsiloxane (PDMS) template [MataA of different-thickness (0.3-1mm), FleischmanAJ, RoyS.CharacterizationofPolydimethylsiloxane (PDMS) PropertiesforBiomedicalMicro/Nanosystems.BiomedicalMicro devices2005; 7:281-293.], hollow out a semicircular area in PDMS template central authorities, PDMS template is placed on a slice to be had
in the glass slide of coating, in hollow region, put into the eggshell membrane handled well, and drip the pre-gelling solution of PEGDA, then add a cover another above
coating [DiazME, CerroRL.Transitionfromsplitstreamlinestodip-coatingdurin gLangmuir-Blodgettfilmdeposition.ThinSolidFilms2004; 460:274-278.] carry thin slice sealing (Fig. 2), be cross-linked with cold white light source or ultraviolet source irradiation and obtain Polyethylene Glycol-protein fibre complex layered materials (Fig. 3), finally the complex layered materials obtained is used chemical crosslinking in glutaraldehyde solution at 4 DEG C, go PBS solution to clean 3 times, obtain Cardiac valve prosthesis (Fig. 4).
Embodiment 1
Raw material and requirement: Fresh Egg film, Polyethylene Glycol, acryloyl chloride, triethanolamine (TEOA), eosin (EosinY), PBS solution, ethanol, NVP (NVP), 40% sodium sulfite solution, ultra-pure water (chemical reagent is analytical pure).
PEGDA synthesizes: reacted by Polyethylene Glycol (PEG) and acryloyl chloride and prepare polyethyleneglycol diacrylate (PEGDA);
Egg film process: remove the egg yolk in raw egg and Ovum Gallus domesticus album, carefully peeled off by eggshell membrane from egg air chamber, washed with de-ionized water 3 times, egg film being immersed in concentration is in the acetic acid of 8mol/L, 4 DEG C process 12 hours, washed with de-ionized water 3 times.The semicircle sample of clip diameter 12mm afterwards, soak at room temperature in mass percent concentration be in the pre-gelling solution of PEGDA white light of 20% 30 minutes;
PDMS template construct: conventional method prepares the thick polydimethylsiloxane of 0.6mm (PDMS) template, hollows out the semicircle shape model of a diameter 12mm in PDMS template central authorities;
Photo-crosslinking: PDMS template is placed on one to be had
in the glass slide of coating, put into the 8 layers of eggshell membrane handled well in hollow region, instill the pre-gelling solution of a small amount of PEGDA white light and be all full of to template hollow region, adding a cover another sheet above has
the microscope slide sealing of coating, irradiates 90 seconds with cold white light source;
Separation cleaning: be carefully separated complex layered artificial heart valve membrane material from template, go PBS solution soaking and washing 3 times;
Molecule crosslinked dose of chemical crosslinking: by complex layered artificial heart valve membrane material 4 DEG C, mass percent concentration be 0.5% glutaraldehyde solution (utilize the NaHCO of 1mol/L
3solution regulates pH value of solution=8) in crosslinked 6 hours, utilize the sodium sulfite solution of mass percent 40% to clean 3 times, then clean 3 times by PBS solution and remove superfluous molecule crosslinked dose, obtain Cardiac valve prosthesis.
Embodiment 2
This example will preparation size be the semicircle shape model of 12mm (diameter) × 0.6mm (thickness) in PDMS template, and choose 6 layers of eggshell membrane handled well and fill PDMS templates, all the other are with embodiment 1.Static tensile test records the elastic modelling quantity 3.43MPa of Cardiac valve prosthesis, and percentage elongation reaches 43%.
Embodiment 3
This example will preparation size be the semicircle shape model of 12mm (diameter) × 0.6mm (thickness) in PDMS template, and choose 4 layers of eggshell membrane handled well and fill PDMS templates, all the other are with embodiment 1.Static tensile test records the elastic modelling quantity 3.30MPa of Cardiac valve prosthesis, and percentage elongation reaches 35%.
Embodiment 4
This example fills choose 4 layers of eggshell membrane handled well with PDMS template, and all the other are with embodiment 1.Mouse back is implanted to subcutaneous after the sample of above-mentioned preparation is cut into 5mmx5mmx0.6mm sample, do not observe rejection phenomenon, also do not observe inflammatory cell to implant part tissue slice HE dyeing (Fig. 5) after 2 weeks, these results illustrate that above-mentioned artificial heart valve membrane material has good biocompatibility.
Embodiment 5
This example will preparation size be the semicircle shape model of 12mm (diameter) × 0.4mm (thickness) in PDMS template, and choose 4 layers of eggshell membrane handled well and fill PDMS templates, all the other are with embodiment 1.By above-mentioned Cardiac valve prosthesis is soaked 2 weeks in type i collagen enzyme (vigor 201u/mg) solution of 1mg/mL, experimental result (Fig. 6) shows sample elastic modulus before and after enzymolysis and there was no significant difference (elastic modelling quantity 3.71MPa before enzymolysis, elastic modelling quantity 3.56MPa after enzymolysis), the artificial valve prepared by proving has the ability of opposing enzymatic degradation.Gained Cardiac valve prosthesis percentage elongation reaches 45%.
Embodiment 6
The pre-gelling solution mass percent concentration of PEGDA that this example uses is 30%, and all the other are with embodiment 1.
Embodiment 7
The pre-gelling solution mass percent concentration of PEGDA that this example uses is 30%, and all the other are with embodiment 3.
Claims (10)
1. prepare Polyethylene Glycol-valvular method of protein fibre combined artificial for one kind, it is characterized in that: the method is for raw material with eggshell membrane and Polyethylene Glycol, first the laminar composite of the coated protein fibre of polyethylene glycol hydrogel is prepared by photo-crosslinking method, then utilize molecule crosslinked dose to carry out chemical crosslinking, obtain described Polyethylene Glycol-protein fibre combined artificial cardiac valve.
2. according to claim 1ly prepare Polyethylene Glycol-valvular method of protein fibre combined artificial, it is characterized in that: the method specifically comprises the steps:
(1) preparation of PEGDA: by Polyethylene Glycol and acryloyl chloride through chemical reactive synthesis and purification polyethyleneglycol diacrylate, i.e. PEGDA;
(2) pretreatment of eggshell membrane: to be immersed in by the eggshell membrane after clean in PBS solution and to be placed in 4 DEG C of refrigerators and store, is cut into the sample of required form and size by eggshell membrane before photo-crosslinking, and be placed in the pre-gelling solution of PEGDA and soak more than 30 minutes;
(3) prepare the PDMS template of required size and thickness, PDMS template central authorities hollow out one with the white space of eggshell membrane sample same shape and size, this PDMS template is placed on a slice to be had
on the microscope slide of coating, in the white space then in PDMS template, place pretreated eggshell membrane sample, sample supplements PEGDA pre-gelling solution again and PDMS template central clear region is filled up, then another sheet has in PDMS template upper cover
the microscope slide sealing of coating;
(4) utilize cold white light or ultraviolet light cross-linking until form the complex layered materials of the coated eggshell membrane of polyethylene glycol hydrogel;
(5) step (4) gained complex layered materials is immersed in molecule crosslinked agent solution, after chemical crosslinking, namely obtains Polyethylene Glycol-protein fibre combined artificial cardiac valve.
3. according to claim 2ly prepare Polyethylene Glycol-valvular method of protein fibre combined artificial, it is characterized in that: in step (2), the cleaning course of eggshell membrane is: remove the egg yolk in raw egg and Ovum Gallus domesticus album, after eggshell membrane and eggshell being peeled off from egg air chamber, use washed with de-ionized water; Then use acid soak method to remove calcium carbonate granule residual on eggshell membrane, then it is clean to spend Ion Cleaning.
4. according to claim 3ly prepare Polyethylene Glycol-valvular method of protein fibre combined artificial, it is characterized in that: use acid soak method to remove CaCO on eggshell membrane
3during granule, the acid solution adopted is the acetum of concentration 1-8mol/L, and the processing time is 2-12 hour, and treatment temperature is 4 DEG C.
5. according to claim 2ly prepare Polyethylene Glycol-valvular method of protein fibre combined artificial, it is characterized in that: in step (2), in the pre-gelling solution of described PEGDA, the pre-gelling solution of PEGDA be cross-linked for cold white light is the PBS solution containing mass percent 10-30%PEGDA, percent by volume 1-2% triethanolamine, 10 μm of ol/L eosins and percent by volume 0.375%N-vinyl pyrrolidone; The pre-gelling solution of PEGDA for ultraviolet light cross-linking is the PBS solution containing 3g/LIrgacure2959.
6. according to claim 2 or 5, prepare Polyethylene Glycol-valvular method of protein fibre combined artificial, it is characterized in that: in step (4), be cross-linked according to cold white light, crosslinking time is 1-2 minute; According to ultraviolet light cross-linking, crosslinking time is 10-30 minute.
7. according to claim 2ly prepare Polyethylene Glycol-valvular method of protein fibre combined artificial, it is characterized in that: in step (3), PDMS template thickness 0.3-1mm, the thickness of PDMS template is determined by the number of plies of adopted eggshell membrane.
8. according to claim 2ly prepare Polyethylene Glycol-valvular method of protein fibre combined artificial, it is characterized in that: in step (5), described molecule crosslinked agent solution is glutaraldehyde solution, glutaraldehyde solution mass percent concentration is 0.25-2%, utilizes the NaHCO of 1mol/L
3solution regulates pH value of solution=8; The chemical crosslinking time is 2-12 hour.
9. according to claim 2ly prepare Polyethylene Glycol-valvular method of protein fibre combined artificial, it is characterized in that: the valvular thickness of prepared combined artificial is determined by the number of plies of eggshell membrane used and the volume of PEGDA hydrogel, and making thickness is according to demand 0.3-1mm; The prepared valvular mechanical strength of combined artificial is determined by the number of plies of eggshell membrane used, the volume of PEGDA hydrogel and concentration.
10. according to claim 1ly prepare Polyethylene Glycol-valvular method of protein fibre combined artificial, it is characterized in that: the valvular elastic modelling quantity >=3.3MPa of prepared combined artificial, percentage elongation is greater than 35%.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510633718.9A CN105326581B (en) | 2015-09-29 | 2015-09-29 | A kind of method for preparing polyethylene glycol protein fiber composite heart valve prosthesis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510633718.9A CN105326581B (en) | 2015-09-29 | 2015-09-29 | A kind of method for preparing polyethylene glycol protein fiber composite heart valve prosthesis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105326581A true CN105326581A (en) | 2016-02-17 |
| CN105326581B CN105326581B (en) | 2017-12-26 |
Family
ID=55277501
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510633718.9A Active CN105326581B (en) | 2015-09-29 | 2015-09-29 | A kind of method for preparing polyethylene glycol protein fiber composite heart valve prosthesis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105326581B (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108904877A (en) * | 2018-08-10 | 2018-11-30 | 中国科学院金属研究所 | Insertion type artificial cardiac valve and preparation method thereof based on macromolecular fibre composite material |
| CN109820624A (en) * | 2018-09-29 | 2019-05-31 | 四川大学 | A method of biovalve is handled using photo-crosslinking |
| CN109833519A (en) * | 2018-10-19 | 2019-06-04 | 四川大学 | A kind of method of bioprosthesis valve |
| WO2020038293A1 (en) * | 2018-08-20 | 2020-02-27 | 杭州启明医疗器械股份有限公司 | Method for treating biological valve using combination of enzymatic cross-linking and tea polyphenol |
| WO2020057412A1 (en) * | 2018-09-19 | 2020-03-26 | 杭州启明医疗器械股份有限公司 | Pre-loadable dried biological heart valve and preparation method thereof |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110279894A (en) * | 2019-06-27 | 2019-09-27 | 中国科学院金属研究所 | Composite material and heart valve prosthesis based on fibroin fiber |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001080921A2 (en) * | 2000-04-20 | 2001-11-01 | Emory University | Native protein mimetic fibers, fiber networks and fabrics for medical use |
| CN1415383A (en) * | 2001-10-29 | 2003-05-07 | 金磊 | Method for modifying tissue material utilized in surgical implantation and modified material |
| CN101128225A (en) * | 2004-12-24 | 2008-02-20 | 塞尔克斯塞尔有限公司 | An implantable biomaterial and a method of producing same |
| CN101461742A (en) * | 2007-12-18 | 2009-06-24 | 复旦大学附属华山医院 | Novel artificial ear drum |
| CN102160899A (en) * | 2010-02-13 | 2011-08-24 | 华中科技大学同济医学院附属协和医院 | Polyethylene glycol crosslinked decellularized valve multi-signal composite scaffold material and preparation method thereof |
| CN103313735A (en) * | 2010-11-17 | 2013-09-18 | 爱德华兹生命科学公司 | Double cross-linkage process to enhance post-implantation bioprosthetic tissue durability |
| WO2013138240A1 (en) * | 2012-03-12 | 2013-09-19 | Colorado State University Research Foundation | Glycosaminoglycan and synthetic polymer materials for blood-contacting applications |
| CN103889472A (en) * | 2011-09-09 | 2014-06-25 | 安多拉米诺科学公司 | Means for controlled sealing of endovascular devices |
-
2015
- 2015-09-29 CN CN201510633718.9A patent/CN105326581B/en active Active
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001080921A2 (en) * | 2000-04-20 | 2001-11-01 | Emory University | Native protein mimetic fibers, fiber networks and fabrics for medical use |
| CN1415383A (en) * | 2001-10-29 | 2003-05-07 | 金磊 | Method for modifying tissue material utilized in surgical implantation and modified material |
| CN101128225A (en) * | 2004-12-24 | 2008-02-20 | 塞尔克斯塞尔有限公司 | An implantable biomaterial and a method of producing same |
| CN101461742A (en) * | 2007-12-18 | 2009-06-24 | 复旦大学附属华山医院 | Novel artificial ear drum |
| CN102160899A (en) * | 2010-02-13 | 2011-08-24 | 华中科技大学同济医学院附属协和医院 | Polyethylene glycol crosslinked decellularized valve multi-signal composite scaffold material and preparation method thereof |
| CN103313735A (en) * | 2010-11-17 | 2013-09-18 | 爱德华兹生命科学公司 | Double cross-linkage process to enhance post-implantation bioprosthetic tissue durability |
| CN103889472A (en) * | 2011-09-09 | 2014-06-25 | 安多拉米诺科学公司 | Means for controlled sealing of endovascular devices |
| WO2013138240A1 (en) * | 2012-03-12 | 2013-09-19 | Colorado State University Research Foundation | Glycosaminoglycan and synthetic polymer materials for blood-contacting applications |
Non-Patent Citations (2)
| Title |
|---|
| ALVARO MATA, ETC: "Characterization of Polydimethylsiloxane(PDMS) Properties for Biomedical Micro/Nanosystems", 《BIOMEDICAL MICRODEVICES》 * |
| ZHANG X, ECT: "Integrating Valve-Inspired Design Features Into Poly(ethylene glycol) hydrogel Scaffolds for Heart Valve Tissue Engineering", 《ACTA BIOMATERIALIA》 * |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108904877A (en) * | 2018-08-10 | 2018-11-30 | 中国科学院金属研究所 | Insertion type artificial cardiac valve and preparation method thereof based on macromolecular fibre composite material |
| WO2020038293A1 (en) * | 2018-08-20 | 2020-02-27 | 杭州启明医疗器械股份有限公司 | Method for treating biological valve using combination of enzymatic cross-linking and tea polyphenol |
| WO2020057412A1 (en) * | 2018-09-19 | 2020-03-26 | 杭州启明医疗器械股份有限公司 | Pre-loadable dried biological heart valve and preparation method thereof |
| CN109820624A (en) * | 2018-09-29 | 2019-05-31 | 四川大学 | A method of biovalve is handled using photo-crosslinking |
| CN109833519A (en) * | 2018-10-19 | 2019-06-04 | 四川大学 | A kind of method of bioprosthesis valve |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105326581B (en) | 2017-12-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105326581A (en) | Method of preparing polyethylene glycol and protein fiber combined artificial cardiac valve | |
| Todros et al. | Biomaterials and their biomedical applications: From replacement to regeneration | |
| Higa et al. | Porous silk fibroin film as a transparent carrier for cultivated corneal epithelial sheets | |
| Brody et al. | Approaches to heart valve tissue engineering scaffold design | |
| CN109157305B (en) | Composite artificial cornea and preparation method thereof | |
| WO2008078157A2 (en) | Bioengineered intervertebral discs and methods for their preparation | |
| CN111450319B (en) | Bionic pre-vascularization material and preparation method and application thereof | |
| Suh | Recent advances in biomaterials | |
| Duan et al. | Progress in the development of a corneal replacement: keratoprostheses and tissue-engineered corneas | |
| WO2019198086A1 (en) | Bioengineered corneal graft and methods of preparation thereof | |
| CN105874060A (en) | Use of mesothelial cells in tissue bioengineering and artificial tissues | |
| Bhat et al. | Biomaterials in regenerative medicine | |
| US20050123520A1 (en) | Generation of living tissue in vivo using a mold | |
| JP2005218585A (en) | Medical material and production method thereof | |
| JPWO2019189786A1 (en) | Cell culture sheet and three-dimensional tissue and its manufacturing method | |
| Kishore et al. | Application of hydrogels in ocular tissue engineering | |
| RU2714943C1 (en) | Artificial cornea, which is a collagen-based heterogeneous stiffness membrane, and a method for production and use thereof | |
| JP7321152B2 (en) | Elastin reduction to allow recellularization of cartilage grafts | |
| KR20210137842A (en) | Membrane for forming biomaterial structure comprising artificial blood vessel, artificial biomaterial structure comprising the membrane and method for manufacturing the same | |
| Fahrenholtz et al. | Development of a heart valve model surface for optimization of surface modifications | |
| Wan et al. | A decellularized porcine pulmonary valved conduit embedded with gelatin | |
| Sokol et al. | Biocompatibility analysis of the decellularized bovine pericardium | |
| KR100970193B1 (en) | Process for preparing transparent collagen substrate used for cornea preparation | |
| Bosch et al. | Design of functional biomaterials as substrates for corneal endothelium tissue engineering | |
| CN110025402B (en) | Artificial cornea containing biological material |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant |